Preclinical CIVO Services

About Presage Biosciences

Presage Biosciences is pioneering a novel approach to cancer drug development with its CIVO platform, a translational tool that allows for the safe, simultaneous testing of multiple microdosed therapies in a single patient's tumor. This technology bridges a critical gap between preclinical models and clinical trials by providing high-resolution, spatial data on molecular and cellular responses in the actual human tumor microenvironment. The company operates both a preclinical services business and has advanced the platform into clinical studies with pharmaceutical partners. Its mission is to de-risk and accelerate oncology drug development by delivering more predictive human data early in the process.

Therapeutic Areas